Histopathological Subtype and Cancer Stem Cell Marker Expression in Advanced Epithelial Ovarian Cancer: A Two-Year Progression-Free Survival Study
World Journal of Oncology · 2026-12 · 17 (6) · 802-810
DOI: 10.14740/wjon2802 ↗At a glance
Journal article in World Journal of Oncology, 2026-12. Written by I. Nyoman Gede Budiana and 1 co-authors. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Late detection and significant recurrence rates make epithelial ovarian cancer (EOC) one of the deadliest gynecologic cancers. Cancer stem cells (CSCs) have been associated with chemoresistance and relapse. However, their prognostic significance remains uncertain. This study examined CSC marker expression in advanced EOC with 2-year progression-free survival (PFS) and the predictive significance of type I/type II classification in histological subtypes.
Methods
We performed an ambispective cohort study of 114 women with advanced EOC who had undergone optimal cytoreductive surgery and standard platinum-based chemotherapy. Expression of CD24, CD44, CD117, CD133, and aldehyde dehydrogenase (ALDH) was studied by immunohistochemistry. PFS was evaluated using Kaplan–Meier methods and correlations were assessed using chi-square or Fisher’s exact test. The predictive value was assessed using receiver operating characteristic (ROC) analysis. Independent predictors of PFS were identified by multivariate Cox regression analysis.
Results
Most patients had stage III disease (60.5%) and were 40–59 years old (65.8%) significantly associated with poor survival (P 0.05) and had poor discrimination in ROC analysis. The combined assessment of CSC markers and histological classification further improved the prognostic stratification and was significantly associated with PFS (P < 0.05). In multivariate analysis, age, tumor stage, and histology type were independent predictors of PFS.
Conclusion
Expression of CSC markers alone is not an independent predictor of 2-year PFS in advanced EOC. Its prognostic relevance is modulated by tumor histology as type I/type II provides a stronger and more consistent prognostic stratification.
Cite
APA
Budiana, I. N. G., & Saspriyana, K. Y. (2026). Histopathological Subtype and Cancer Stem Cell Marker Expression in Advanced Epithelial Ovarian Cancer: A Two-Year Progression-Free Survival Study. World Journal of Oncology, 17(6), 802-810. https://doi.org/10.14740/wjon2802
Vancouver
Budiana ING, Saspriyana KY. Histopathological Subtype and Cancer Stem Cell Marker Expression in Advanced Epithelial Ovarian Cancer: A Two-Year Progression-Free Survival Study. World Journal of Oncology. 2026;17(6):802-810. doi:10.14740/wjon2802
BibTeX
@article{Budiana2026,
author = {Budiana, I. Nyoman Gede and Saspriyana, Kade Yudi},
title = {Histopathological Subtype and Cancer Stem Cell Marker Expression in Advanced Epithelial Ovarian Cancer: A Two-Year Progression-Free Survival Study},
journal = {World Journal of Oncology},
year = {2026},
volume = {17},
number = {6},
pages = {802--810},
doi = {10.14740/wjon2802}
}
EUVIMED